🟢 EIQ.AX is trading 44% up today on speculation of FDA clearance for its heart failure AI tool

EIQ.AX is trading 44% up at A$1.78 following a sharp speculative rally tied to expectations of an imminent U.S. FDA decision on its AI-powered heart failure diagnostic tool.

• Investors are reacting to commentary that Echo IQ’s FDA 510(k) clearance for EchoSolv-HF could arrive in early 2026, expanding its U.S. cardiology AI platform.
• The rally builds on momentum from the company's existing FDA-cleared aortic stenosis product, despite Echo IQ currently generating minimal revenue.